首页> 美国卫生研究院文献>other >Potent Suppression of Viral Infectivity by the Peptides That Inhibit Multimerization of Human Immunodeficiency Virus Type 1 (HIV-1) Vif Proteins
【2h】

Potent Suppression of Viral Infectivity by the Peptides That Inhibit Multimerization of Human Immunodeficiency Virus Type 1 (HIV-1) Vif Proteins

机译:通过抑制人类免疫缺陷病毒1型(HIV-1)Vif蛋白多聚的肽有效抑制病毒感染性。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Virion infectivity factor (Vif) is essential for the replication of human immunodeficiency virus type 1 (HIV-1) in vivo, but its function remains uncertain. Recently, we have shown that Vif proteins are able to form multimers, including dimers, trimers, or tetramers. Because the multimerization of Vif proteins is required for Vif function in the viral life cycle, we propose that it could be a novel target for anti-HIV-1 therapeutics. Through a phage peptide display method, we have identified a set of 12-mer peptides containing a PXP motif that binds to HIV-1 Vif protein. These proline-enriched peptides potently inhibited the Vif-Vif interaction in vitro. We have also screened a set of synthesized Vif peptides (15-mer), which covers all the amino acids of the HIV-1 Vif protein sequence, for their ability to inhibit the Vif-Vif interaction in vitro. We demonstrated that Vif-derived proline-enriched peptides that contain the 161PPLP164 domain are able to inhibit the Vif-Vif interaction. Conversely, the deletion of the 161PPLP164 domain of Vif protein will significantly impair the capability of Vif proteins to interact with each other, indicating that the 161PPLP164 domain plays a key role in Vif multimerization. All these results demonstrate that the proline-enriched peptides block the multimerization of Vif through interfering with the polyproline interfaces of Vif formed by 161PPLP164 domain. Moreover, these peptides which inhibit the Vif-Vif interaction in vitro potently inhibit HIV-1 replication in the “nonpermissive” T-cells. We propose that this study starts a novel strategy to develop structural diverse inhibitors of Vif such as peptidomimetics or small organic molecules.
机译:病毒颗粒感染因子(Vif)对于在体内复制1型人类免疫缺陷病毒(HIV-1)至关重要,但其功能仍不确定。最近,我们显示Vif蛋白能够形成多聚体,包括二聚体,三聚体或四聚体。由于Vif蛋白在病毒生命周期中的功能是必需的,因此建议将其作为抗HIV-1治疗药物的新靶标。通过噬菌体肽展示方法,我们已经鉴定出一套12-mer肽,其中包含与HIV-1 Vif蛋白结合的PXP基序。这些富含脯氨酸的肽在体外可有效抑制Vif-Vif相互作用。我们还筛选了一组合成的Vif肽(15-聚体),它们涵盖了HIV-1 Vif蛋白序列的所有氨基酸,具有抑制Vif-Vif体外相互作用的能力。我们证明了包含 161 PPLP 164 域的Vif衍生的富含脯氨酸的肽能够抑制Vif-Vif相互作用。相反,删除Vif蛋白的 161 PPLP 164 域将显着削弱Vif蛋白彼此相互作用的能力,表明 161 PPLP 164 域在Vif多聚化中起关键作用。所有这些结果表明,富含脯氨酸的肽通过干扰由 161 PPLP 164 域形成的Vif的多脯氨酸界面来阻断Vif的多聚化。此外,这些在体外抑制Vif-Vif相互作用的肽可有效抑制HIV-1在“非许可” T细胞中的复制。我们建议这项研究开始一种新的策略,以开发Vif的结构多样的抑制剂,例如拟肽或有机小分子。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号